Prediction of drug-drug Interactions Between Various Antidepressants and Efavirenz or Boosted Protease Inhibitors Using a Physiologically Based Pharmacokinetic Modelling Approach
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Prediction of drug-drug Interactions Between Various Antidepressants and Efavirenz or Boosted Protease Inhibitors Using a Physiologically Based Pharmacokinetic Modelling Approach
Authors
Keywords
Fluoxetine, Venlafaxine, Efavirenz, Mirtazapine, Intrinsic Clearance
Journal
CLINICAL PHARMACOKINETICS
Volume 52, Issue 7, Pages 583-592
Publisher
Springer Nature America, Inc
Online
2013-03-11
DOI
10.1007/s40262-013-0056-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Pharmacokinetic and Pharmacodynamic Analysis of Efavirenz Dose Reduction Using an In Vitro–In Vivo Extrapolation Model
- (2012) M Siccardi et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Current prospects for interferon-free treatment of hepatitis C in 2012
- (2012) Catherine AM Stedman JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Induction of drug efflux protein expression by venlafaxine but not desvenlafaxine
- (2011) Corbin J. Bachmeier et al. BIOPHARMACEUTICS & DRUG DISPOSITION
- Interplay of Metabolism and Transport in Determining Oral Drug Absorption and Gut Wall Metabolism: A Simulation Assessment Using the “Advanced Dissolution, Absorption, Metabolism (ADAM)” Model
- (2011) A. S. Darwich et al. CURRENT DRUG METABOLISM
- Complex Drug Interactions of HIV Protease Inhibitors 2: In Vivo Induction and In Vitro to In Vivo Correlation of Induction of Cytochrome P450 1A2, 2B6, and 2C9 by Ritonavir or Nelfinavir
- (2011) B. J. Kirby et al. DRUG METABOLISM AND DISPOSITION
- Complex Drug Interactions of HIV Protease Inhibitors 1: Inactivation, Induction, and Inhibition of Cytochrome P450 3A by Ritonavir or Nelfinavir
- (2011) B. J. Kirby et al. DRUG METABOLISM AND DISPOSITION
- Prevalence of comedications and effect of potential drug–drug interactions in the Swiss HIV Cohort Study
- (2010) Catia Marzolini et al. ANTIVIRAL THERAPY
- A Marginal Structural Model to Estimate the Causal Effect of Antidepressant Medication Treatment on Viral Suppression Among Homeless and Marginally Housed Persons With HIV
- (2010) Alexander C. Tsai et al. ARCHIVES OF GENERAL PSYCHIATRY
- In silico prediction of efavirenz and rifampicin drug-drug interaction considering weight and CYP2B6 phenotype
- (2010) Dinko Rekić et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Atazanavir Metabolism According to CYP3A5 Status: An In Vitro-In Vivo Assessment
- (2010) M. F. Wempe et al. DRUG METABOLISM AND DISPOSITION
- Selection of Alternative CYP3A4 Probe Substrates for Clinical Drug Interaction Studies Using In Vitro Data and In Vivo Simulation
- (2010) R. S. Foti et al. DRUG METABOLISM AND DISPOSITION
- In Situ Intestinal Perfusion in Knockout Mice Demonstrates Inhibition of Intestinal P-Glycoprotein by Ritonavir Causing Increased Darunavir Absorption
- (2010) N. Holmstock et al. DRUG METABOLISM AND DISPOSITION
- Efavirenz Primary and Secondary Metabolism In Vitro and In Vivo: Identification of Novel Metabolic Pathways and Cytochrome P450 2A6 as the Principal Catalyst of Efavirenz 7-Hydroxylation
- (2010) E. T. Ogburn et al. DRUG METABOLISM AND DISPOSITION
- Pharmacokinetics of plasma lopinavir/ritonavir following the administration of 400/100 mg, 200/150 mg and 200/50 mg twice daily in HIV-negative volunteers
- (2010) A. Jackson et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Dose-Related Reduction in Bupropion Plasma Concentrations by Ritonavir
- (2010) Joohyun Park et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Glucuronidation of the Antiretroviral Drug Efavirenz by UGT2B7 and an in Vitro Investigation of Drug-Drug Interaction with Zidovudine
- (2009) A.-S. Belanger et al. DRUG METABOLISM AND DISPOSITION
- The Simcyp®Population-based ADME Simulator
- (2009) Masoud Jamei et al. Expert Opinion on Drug Metabolism & Toxicology
- Pharmacokinetics, Efficacy, and Safety of Darunavir/Ritonavir 800/100 mg Once-Daily in Treatment-Naïve and -Experienced Patients
- (2009) Marta Boffito et al. HIV CLINICAL TRIALS
- Induction of Multiple Drug Transporters by Efavirenz
- (2009) Johanna Weiss et al. JOURNAL OF PHARMACOLOGICAL SCIENCES
- Sertraline and Its Metabolite Desmethylsertraline, but not Bupropion or Its Three Major Metabolites, Have High Affinity for P-Glycoprotein
- (2008) Jun-Sheng Wang et al. BIOLOGICAL & PHARMACEUTICAL BULLETIN
- Effects of CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers
- (2008) Samantha Abel et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Maraviroc:in vitroassessment of drug-drug interaction potential
- (2008) Ruth Hyland et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Effects of CYP3A4 inducers with and without CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers
- (2008) Samantha Abel et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- A Combined Model for Predicting CYP3A4 Clinical Net Drug-Drug Interaction Based on CYP3A4 Inhibition, Inactivation, and Induction Determined in Vitro
- (2008) O. A. Fahmi et al. DRUG METABOLISM AND DISPOSITION
- Prescribing patterns of antidepressants in Europe: Results from the Factors Influencing Depression Endpoints Research (FINDER) study
- (2008) Michael Bauer et al. EUROPEAN PSYCHIATRY
- Atazanavir and lopinavir with ritonavir alone or in combination: analysis of pharmacokinetic interaction and predictors of drug exposure
- (2008) S Di Giambenedetto et al. HIV MEDICINE
- Efavirenz Induces CYP2B6-Mediated Hydroxylation of Bupropion in Healthy Subjects
- (2008) Sarah M Robertson et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started